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RESULTS

BACKGROUND
o
o
o
o

Pancreatic ductal adenocarcinoma (PDAC) has a dismal 5-year survival rate of
8% and the 3rd highest mortality rate of all cancers in Canada1
PDAC is characterized by the increased proliferation of cancer associated
fibroblasts (CAFs)2
CAFs are a potential predictor of clinical outcome and therapeutic target3
CAFs can categorized into myofibroblastic CAFs (myCAFs) and inflammatory
CAFs (iCAFs)2,3
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Figure 3. Cultured cells exhibit
morphology characteristic of
CAFs. Samples were imaged
using phase contrast
microscopy. CAFs (arrow)
from EUS 15 appear to grow
more slowly to EUS 8.
Magnification bars = 200 µm.
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Figure 1. myCAFs (red) and iCAFs (blue) differ in protein expression and
proximity to tumour cells. myCAFs have a greater expression of alpha smooth
muscle actin (⍺SMA) and are found in closer proximity to cancer cells
compared to iCAFs.

o
o
o

It is unclear how CAF populations and the proportion of myCAFs differ
between patients
While an abundance of myCAFs correlates with poor prognosis, myCAF
depletion has also been shown to promote PDAC progression4
Therefore, the heterogeneity of CAF populations require further investigation

HYPOTHESIS & OBJECTIVE

Figure 4. Patient samples express different amounts of the myCAF marker, ⍺SMA.
(A) Western blot analysis for ⍺SMA, vimentin and tubulin (used as a loading
control). (B) The ratio of ⍺SMA to vimentin was compared between CAF lines. The
ratios were obtained through the densitometric analysis of the Western blots
shown in A. EUS 15 and 253 displayed greater ratios of ⍺SMA to vimentin, which is
a general fibroblast marker, compared to EUS 8 and EUS 10.
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*Percentages were determined through quantification of immunofluorescent
staining (see Figure 5). Passage number and method of collection are shown.

CONCLUSION AND FUTURE DIRECTIONS
The results of these experiments identify heterogeneity in the proportion of ⍺SMA
positive cells within a population and the level of ⍺SMA expression within a cell.
While EUS 8 and EUS 10 appear to express similar amounts of ⍺SMA based on
western blot analysis (Figure 4) immunofluorescent staining (Figure 5) reveals
differences in the intensity and number of ⍺SMA positive cells. For example, a
larger proportion (89.9%)of EUS 8 fibroblasts stain positive for ⍺SMA compared to
EUS 10 (52.07%), but at lower levels.

Future Directions:
1. Correlate the fibroblast population makeup with patient clinical outcomes
2. Determine the ratio or myCAFs to iCAFs using IL-6, an iCAF marker.
3. Perform global gene expression analysis to compare CAF populations within
(single cell) and between patients
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Figure 2. CAFs were isolated from samples obtained through endoscopic ultrasound
(EUS) biopsies or surgical resection. Isolated CAFs were cultured in Dulbecco's
Modified Eagle Medium (DMEM) with 2% PenStrep and 10% fetal bovine serum.
Western blotting and immunofluorescent staining were then used to characterize
the fibroblasts at various culture passages.
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Identifying the characteristics of a patient’s CAFs could help inform diagnosis and
therapy. CAFs may be a potential therapeutic target.

Hypothesis: Distinguishable differences in the CAF populations between patients
can help predict PDAC progression and sensitivity therapy
Objective: Characterize CAFs from PDAC tumours to identify differences between
patients.

Table 1. Percentage of ⍺SMA positive cells vary between patient samples.

Figure 5. Heterogeneity in patient CAF populations. Co-immunofluorescent
staining of ⍺SMA (red) and vimentin (green) show different proportion of ⍺SMA+
CAFs (EUS 10 vs. 253) and different intensities of ⍺SMA accumulation (EUS 8 vs.
EUS 15). Samples correspond to those in previous figure. White arrows indicate
fibroblasts that do not express ⍺SMA. Magnification bars = 50 µm.

